Ginkgo Bioworks (DNA)
(Delayed Data from NYSE)
$0.27 USD
-0.02 (-5.46%)
Updated Aug 9, 2024 04:00 PM ET
Pre-Market: $0.26 -0.01 (-3.77%) 8:58 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
DNA 0.27 -0.02(-5.46%)
Will DNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNA
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
DNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Other News for DNA
Ginkgo Bioworks: From Growth To Value
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
DNA Stock Earnings: Ginkgo Bioworks Holdings Misses EPS, Beats Revenue for Q2 2024
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2024 Earnings Call Transcript